Dual-Target CSPG4/GD2 CAR-NK Cells for Advanced Melanoma

This is a first-in-human, open-label, multicenter phase 1/2 study evaluating the safety, feasibility, recommended phase 2 dose (RP2D), and preliminary antitumor activity of allogeneic dual-target CSPG4/GD2 CAR-NK cells (EBDTKN-401) after lymphodepleting chemotherapy in adults with unresectable or metastatic cutaneous melanoma or metastatic uveal melanoma whose disease has progressed after standard therapy

NCT Number	NCT07627698
Lead Sponsor	Beijing Biotech
Conditions	Unresectable Melanoma, Metastatic Cutaneous Melanoma, Metastatic Uveal Melanoma
Enrollment	36 participants
Start Date	2026-03-02
Primary Completion	2027-06-14 (estimated)
Study Completion	2028-06-17 (estimated)
Updated on ClinicalTrials.gov	2026-06-04